Non-small cell lung cancer (NSCLC) Clinical Trials in Los Angeles, CA

As of June 2026, 58 paid clinical trials are recruiting for Non-small cell lung cancer (NSCLC) in Los Angeles, California. Lung cancer research focuses on targeted therapies for specific mutations such as EGFR, ALK, and KRAS, alongside immunotherapy regimens. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Related specialties in Los Angeles

Oncology· 851 Lung oncology· 84

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

58 clinical trials for Non-small cell lung cancer (NSCLC)

·Clear filters·↓ Download CSV

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

for Non Small Cell Lung Cancer

Drug: Osimertinib

5 locations incl. Beverly Hills

Sponsor: Karen Reckamp, MD, MS

Sex: All·Age: 18+

Code: NCT05401110·Phase 1·Recruiting

Apply to this trial

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

for Head and Neck Squamous Cell Carcinoma (HNSCC)

4 locations incl. Los Angeles

Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT05985655·Phase 1, Phase 2·Recruiting

Apply to this trial

TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

for Renal Cell Cancer

3 locations incl. Los Angeles

Sponsor: Portage Biotech

Sex: All·Age: 18+

Code: NCT04969315·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

for Solid Tumor, Adult

13 locations incl. Los Angeles

Sponsor: GV20 Therapeutics

Sex: All·Age: 18+

Code: NCT05669430·Phase 1, Phase 2·Recruiting

Apply to this trial

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

for High Grade Epithelial Ovarian Cancer

37 locations incl. Phoenix

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT05579366·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

for Melanoma

58 locations incl. Birmingham

Sponsor: Pfizer

Sex: All·Age: 16+

Code: NCT05538130·Phase 1·Recruiting

Apply to this trial

A Study of EP0031 in Patients With Advanced RET-altered Malignancies

for Advanced Solid Tumor

Drug: EP0031

18 locations incl. Los Angeles

Sponsor: Ellipses Pharma

Sex: All·Age: 18+

Code: NCT05443126·Phase 1, Phase 2·Recruiting

Apply to this trial

GEMINI-NSCLC: NSCLC Biomarker Study

for Non-Small Cell Lung Cancer

58 locations incl. Birmingham

Sponsor: Tempus AI

Sex: All·Age: 18+

Code: NCT05236114·Recruiting

Apply to this trial

Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers

for NSCLC

21 locations incl. Davis

Sponsor: Lung Cancer Mutation Consortium

Sex: All·Age: All ages

Code: NCT04712877·Recruiting

Apply to this trial

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

for Non-small Cell Lung Cancer

25 locations incl. Little Rock

Sponsor: AstraZeneca

Sex: All·Age: 18 - 95

Code: NCT05061550·Phase 2·Recruiting

Apply to this trial

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for Non Small Cell Lung Cancer

Drug: Telisotuzumab Vedotin

50 locations incl. Birmingham

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT04928846·Phase 3·Recruiting

Apply to this trial

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

for Advanced Solid Tumor

9 locations incl. Fullerton

Sponsor: TORL Biotherapeutics, LLC

Sex: All·Age: 18+

Code: NCT05103683·Phase 1·Recruiting

Apply to this trial

A Study of NX-1607 in Adults With Advanced Malignancies

for Ovarian Cancer, Epithelial

10 locations incl. Duarte

Sponsor: Nurix Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05107674·Phase 1·Recruiting

Apply to this trial

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

for Non-small Cell Lung Cancer

38 locations incl. Duarte

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT04302025·Phase 2·Recruiting

Apply to this trial

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

for Advanced Solid Tumor

32 locations incl. Irvine

Sponsor: PMV Pharmaceuticals, Inc

Sex: All·Age: 12+

Code: NCT04585750·Phase 1, Phase 2·Recruiting

Apply to this trial

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

for Lung Non-Small Cell Carcinoma

1150 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04267848·Phase 3·Recruiting

Apply to this trial

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

for Advanced/Metastatic Solid Tumors

23 locations incl. La Jolla

Sponsor: Merus B.V.

Sex: All·Age: 18+

Code: NCT03526835·Phase 1, Phase 2·Recruiting

Apply to this trial

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

for Solid Tumors

6 locations incl. Los Angeles

Sponsor: Apollomics Inc.

Sex: All·Age: 18+

Code: NCT03175224·Phase 2·Recruiting

Apply to this trial